Aurobindo Pharma Reports Q1FY26 Revenue Growth of 4.0% YoY to INR 7,868 Cr

Aurobindo Pharma Limited has announced its consolidated financial results for the quarter ended June 30, 2025. The company's revenue from operations increased by 4.0% YoY to INR 7,868 Cr. US formulations revenue marginally declined by 1.9% YoY to INR 3,488 Cr, accounting for 44.3% of consolidated revenue. Europe formulations revenue increased by 18.0% YoY to INR 2,338 Cr, accounting for 29.7% of consolidated revenue. Growth Markets formulations revenue increased by 8.8% YoY to INR 772 Cr. ARV business revenue increased by 55.2% YoY to INR 355 Cr. APl revenues decreased by 16.1% YoY to INR 916 Cr. The company received final approval for 14 ANDAs from the USFDA during the quarter.